Consultations and Updates to the List

As per the Health (Pricing and Supply of Medical Goods) Act 2013, the HPRA is required to consult with relevant marketing authorisation holders prior to adding a medicine or a group of medicines to the list of interchangeable medicines. 

Full details on the general consultation process and the possible outcomes are provided in the Guide to Interchangeable Medicines.

The HPRA was directed by the Department of Heath to assess the interchangeability of a number of active substances in 2014. The following consultation remains:

Oxycodone

The HPRA received an additional list of active substances from the Department of Health in 2016.

Details of ongoing and completed consultations, and resulting updates to the list of interchangeable medicines, are provided below:

Ongoing Consultations

Please note that the HPRA cannot comment or provide any further information on specific consultations.

Clarithromycin: The review consultation process for Clarithromycin with the relevant marketing authorisation holders has commenced. It will conclude on 20th November 2017. The date of publication will be decided thereafter.

Latanoprost: The consultation process for Latanoprost with the relevant marketing authorisation holders has commenced. It will conclude on 25 April 2017. The date of publication will be decided thereafter.

Lactulose: The consultation process for Lactulose with the relevant marketing authorisation holders has commenced. It will conclude on 18 April 2017. The date of publication will be decided thereafter.

Amlodipine: The review consultation process for Amlodipine with the relevant marketing authorisation holders has commenced. It will conclude on 28 March 2017. The date of publication will be decided thereafter.

Salbutamol: The consultation process for Salbutamol with the relevant marketing authorisation holders has commenced. It will conclude on 13 February 2015. The date of publication will be decided thereafter.

Perindopril: The review consultation process for Perindopril with the relevant marketing authorisation holders has commenced. It will conclude on 13 January 2015. The date of publication will be decided thereafter.

Acetylsalicylic acid: The consultation process for Acetylsalicylic acid with the relevant marketing authorisation holders has commenced. It will conclude on 05 June 2014. The date of publication will be decided thereafter.​

Completed Consultations 

Sildenafil: The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 17 November 2017.

Tamsulosin: The consultation process for Tamsulosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tamsulosin medicines, was published on 25 October 2017.

Levocetirizine: The consultation process for Levocetirizine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Levocetirizine medicines, was published on 25 October 2017.

Flurazepam: The consultation process for Flurazepam with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Flurazepam medicines, was published on 18 October 2017.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 04 October 2017.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Venlafaxine medicines, was published on 06 September 2017.

Risedronic Acid: The consultation process for Risedronic Acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Risedronic Acid medicines, was published on 23 August 2017.

Clopidogrel: The consultation process for Clopidogrel with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clopidogrel medicines, was published on 10 August 2017.

Simvastatin: The consultation process for Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Simvastatin medicines, was published on 25 July 2017.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 29 June 2017.

Clarithromycin: The consultation process for Clarithromycin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clarithromycin medicines, was published on 21 June 2017.

Citalopram: The consultation process for Citalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Citalopram medicines, was published on 14 June 2017.

Pantoprazole: The consultation process for Pantoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Pantoprazole medicines, was published on 14 June 2017.

Methotrexate: The consultation process for Methotrexate with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Methotrexate medicines, was published on 31 May 2017.

Sildenafil: The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 17 May 2017.

Donepezil: The consultation process for Donepezil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Donepezil medicines, was published on 17 May 2017.

Lansoprazole: The consultation process for Lansoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lansoprazole medicines, was published on 10 May 2017.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 26 April 2017.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 26 April 2017.

Levocetirizine: The consultation process for Levocetirizine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Levocetirizine medicines, was published on 26 April 2017.

Omeprazole: The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 19 April 2017.

Flucloxacillin: The consultation process for Flucloxacillin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Flucloxacillin medicines, was published on 12 April 2017.

Ranitidine: The consultation process for Ranitidine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Ranitidine medicines, was published on 05 April 2017.

Cetirizine: The consultation process for Cetirizine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Cetirizine medicines, was published on 29 March 2017.

Betahistine: The consultation process for Betahistine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Betahistine medicines, was published on 22 March 2017.

Domperidone: The consultation process for Domperidone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Domperidone medicines, was published on 15 March 2017.

Tramadol/Paracetamol: The consultation process for Tramadol/Paracetamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol/Paracetamol medicines, was published on 15 March 2017.

Nebivolol: The consultation process for Nebivolol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Nebivolol medicines, was published on 08 March 2017.

Tolterodine:
The consultation process for Tolterodine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tolterodine medicines, was published on 22 February 2017.

Fluoxetine: The consultation process for Fluoxetine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Fluoxetine medicines, was published on 18 January 2017.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 22 December 2016.

Gliclazide: The consultation process for Gliclazide with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Gliclazide medicines, was published on 21 December 2016.

Alendronic acid: The consultation process for Alendronic acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Alendronic acid medicines, was published on 21 December 2016.

Alprazolam: The consultation process for Alprazolam with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Alprazolam medicines, was published on 14 December 2016.

Duloxetine: The consultation process for Duloxetine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Duloxetine medicines, was published on 07 December 2016.

Aripiprazole:
The consultation process for Aripiprazole with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Aripiprazole medicines, was published on 22 November 2016.

Metformin: The consultation process for Metformin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Metformin medicines, was published on 28 September 2016.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 28 September 2016.

Amlodipine: The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 21 September 2016.

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan medicines, was published on 14 September 2016.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 14 September 2016.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 31 August 2016.

Tramadol/Paracetamol: The consultation process for Tramadol/Paracetamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol/Paracetamol medicines, was published on 31 August 2016.

Ramipril: The consultation process for Ramipril with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ramipril medicines, was published on 06 July 2016.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 29 June 2016.

Sertraline: The consultation process for Sertraline with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sertraline medicines, was published on 29 June 2016.

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan medicines, was published on 30 March 2016.

Rosuvastatin:
The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 23 March 2016.

​Amlodipine:
The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 23 March 2016.

Bisoprolol: The consultation process for Bisoprolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Bisoprolol medicines, was published on 24 February 2016.

Capecitabine: The consultation process for Capecitabine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Capecitabine medicines, was published on 03 February 2016.

Amoxicillin/Clavulanic acid: The consultation process for Amoxicillin/Clavulanic acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amoxicillin/Clavulanic acid medicines, was published on 20 January 2016.

Lansoprazole: The consultation process for Lansoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lansoprazole medicines, was published on 18 November 2015.

Alendronic acid: The consultation process for Alendronic acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Alendronic acid medicines, was published on 11 November 2015.

Risperidone: The consultation process for Risperidone with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Risperidone medicines, was published on 04 November 2015.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 14 October 2015.

Escitalopram: The consultation process for Escitalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Escitalopram medicines, was published on 07 October 2015.

Omeprazole: The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 07 October 2015.

Amlodipine: The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 30 September 2015.

Diclofenac: The consultation process for Diclofenac with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Diclofenac medicines, was published on 30 September 2015.

Simvastatin: The consultation process for Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Simvastatin medicines, was published on 23 September 2015.
 

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan medicines, was published on 23 September 2015.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Venlafaxine medicines, was published on 16 September 2015.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 16 September 2015.

Clopidogrel:
 The consultation process for Clopidogrel with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clopidogrel medicines, was published on 12 August 2015.

Anastrazole: The consultation process for Anastrazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Anastrazole medicines, was published on 12 August 2015.

Pantoprazole:
 The consultation process for Pantoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Pantoprazole medicines, was published on 29 July 2015.

Co-amoxiclav: 
The consultation process for Co-amoxiclav with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Co-amoxiclav medicines, was published on 03 July 2015.

Bisoprolol:
 The consultation process for Bisoprolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Bisoprolol medicines, was published on 17 June 2015.

Montelukast: The consultation process for Montelukast with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Montelukast medicines, was published on 10 June 2015.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 03 June 2015.

Donepezil: The consultation process for Donepezil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Donepezil medicines, was published on 27 May 2015.

Lansoprazole: The consultation process for lansoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lansoprazole medicines, was published on 20 May 2015.

Pravastatin: The consultation process for Pravastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Pravastatin medicines, was published on 22 April 2015.

Escitalopram: The consultation process for Escitalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Escitalopram medicines, was published on 01 October 2015.

Esomeprazole: The consultation process for Esomeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Esomeprazole medicines, was published on 19 March 2015.

Amlodipine: The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 19 March 2015.

Metformin: The consultation process for Metformin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Metformin medicines, was published on 19 March 2015.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 11 March 2015.

Losartan: The consultation process for Losartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Losartan medicines, was published on 4 March 2015.

Tramadol: The consultation process for Tramadol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Tramadol medicines, was published on 18 February 2015.

Capecitabine: The consultation process for Capecitabine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Capecitabine medicines, was published on 20 January 2015.

Temozolomide: The consultation process for Temozolomide with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Temozolomide medicines, was published on 20 January 2015.

Fluoxetine: The consultation process for Fluoxetine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Fluoxetine medicines, was published on 18 December 2014.

Paroxetine:
The consultation process for Paroxetine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Paroxetine medicines, was published on 17 December 2014.

Clarithromycin: The consultation process for Clarithromycin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Clarithromycin medicines, was published on 10 December 2014.

Citalopram: The consultation process for Citalopram with the relevant marketing authorisation holders has been completed.  The initial list, including interchangeable Citalopram medicines, was published on 10 December 2014.

Alendronic acid: The consultation process for Alendronic acid with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Alendronic acid medicines, was published on 19 November 2014.

Tamsulosin: The consultation process for Tamsulosin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Tamsulosin medicines, was published on 08 October 2014.

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Telmisartan medicines, was published on 04 September 2014.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Venlafaxine medicines, was published on 27 August 2014.

Risedronic Acid: The consultation process for Risedronic Acid with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Risedronic Acid medicines, was published on 21 August 2014.

Zopiclone: The consultation process for Zopiclone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Zopiclone medicines, was published on 07 August 2014.

Diclofenac: The consultation process for Diclofenac with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Diclofenac medicines, was published on 24 July 2014.

Doxazosin: The consultation process for Doxazosin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Doxazosin medicines, was published on 10 July 2014.

Perindopril: The consultation process for Perindopril with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Perindopril medicines, was published on 10 July 2014.

Mirtazapine: The consultation process for Mirtazapine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Mirtazapine medicines, was published on 08 July 2014.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Valsartan medicines, was published on 27 June 2014.

Bisoprolol: The consultation process for Bisoprolol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Bisoprolol medicines, was published on 19 June 2014.

Montelukast: The consultation process for Montelukast with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Montelukast medicines, was published on 29 May 2014.

Tolterodine: The consultation process for Tolterodine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tolterodine medicines, was published on 25 February 2015.

Ramipril: The consultation process for Ramipril with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ramipril medicines, was published on 20 January 2015.

Sertraline:
The consultation process for Sertraline with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sertraline medicines, was published on 14 October 2014.

Sildenafil: The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 26 November 2014.

Memantine: The consultation process for Memantine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Memantine medicines, was published on 19 November 2014.

Risperidone: The consultation process for Risperidone with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Risperidone medicines, was published on 14 October 2014.

Olanzapine: The consultation process for Olanzapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Olanzapine medicines, was published on 09 October 2014.

Candesartan: The consultation process for Candesartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Candesartan medicines, was published on 05 Spetember 2014

Rabeprazole: The consultation process for Rabeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable rabeprazole medicines, was published on 18 August 2014.

Simvastatin: The consultation process for Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Simvastatin medicines, was published on 23 May 2014.

Co-Amoxiclav: The consultation process for Co-Amoxiclav with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Co-Amoxiclav medicines, was published on 15 October 2014.

Lercanidipine: The consultation process for lercanidipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable lercanidipine medicines, was published on 17 June 2014.

Pantoprazole: The consultation process for pantoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable pantoprazole medicines, was published on 18 December 2014.

Omeprazole: The consultation process for omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable omeprazole medicines, was published on 07 October 2015.

Rosuvastatin: The consultation process for rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable rosuvastatin medicines, was published on 23 September 2014.